AU2017260806B9 - Markers of endometrial cancer - Google Patents

Markers of endometrial cancer Download PDF

Info

Publication number
AU2017260806B9
AU2017260806B9 AU2017260806A AU2017260806A AU2017260806B9 AU 2017260806 B9 AU2017260806 B9 AU 2017260806B9 AU 2017260806 A AU2017260806 A AU 2017260806A AU 2017260806 A AU2017260806 A AU 2017260806A AU 2017260806 B9 AU2017260806 B9 AU 2017260806B9
Authority
AU
Australia
Prior art keywords
ldha
mmp9
level
perm
nampt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017260806A
Other languages
English (en)
Other versions
AU2017260806B2 (en
AU2017260806A1 (en
Inventor
Eva COLÁS ORTEGA
Bruno Domon
Antonio Gil Moreno
Antoine LESUR
Elena MARTINEZ GARCÍA
Jaume REVENTÓS PUIGJANER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Original Assignee
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut de Recerca Hospital Universitari Vall dHebron filed Critical Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Publication of AU2017260806A1 publication Critical patent/AU2017260806A1/en
Assigned to FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA reassignment FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA Request for Assignment Assignors: FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA, INSTITUT DE RECERCA BIOMÈDICA DE LLEIDA FUNDACIÓ DR. PIFARRÉ, LUXEMBOURG INSTITUTE OF HEALTH (LIH)
Publication of AU2017260806B2 publication Critical patent/AU2017260806B2/en
Application granted granted Critical
Publication of AU2017260806B9 publication Critical patent/AU2017260806B9/en
Priority to AU2023210591A priority Critical patent/AU2023210591B9/en
Priority to AU2025223935A priority patent/AU2025223935A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017260806A 2016-05-04 2017-03-30 Markers of endometrial cancer Active AU2017260806B9 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023210591A AU2023210591B9 (en) 2016-05-04 2023-08-02 Markers of endometrial cancer
AU2025223935A AU2025223935A1 (en) 2016-05-04 2025-09-01 Markers of endometrial cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16168328 2016-05-04
EP16168328.9 2016-05-04
PCT/EP2017/057635 WO2017190896A1 (en) 2016-05-04 2017-03-30 Mmp9 as marker of endometrial cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023210591A Division AU2023210591B9 (en) 2016-05-04 2023-08-02 Markers of endometrial cancer

Publications (3)

Publication Number Publication Date
AU2017260806A1 AU2017260806A1 (en) 2018-12-13
AU2017260806B2 AU2017260806B2 (en) 2023-06-15
AU2017260806B9 true AU2017260806B9 (en) 2023-07-20

Family

ID=56096908

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017260806A Active AU2017260806B9 (en) 2016-05-04 2017-03-30 Markers of endometrial cancer
AU2023210591A Active AU2023210591B9 (en) 2016-05-04 2023-08-02 Markers of endometrial cancer
AU2025223935A Pending AU2025223935A1 (en) 2016-05-04 2025-09-01 Markers of endometrial cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023210591A Active AU2023210591B9 (en) 2016-05-04 2023-08-02 Markers of endometrial cancer
AU2025223935A Pending AU2025223935A1 (en) 2016-05-04 2025-09-01 Markers of endometrial cancer

Country Status (12)

Country Link
US (2) US20190137499A1 (enExample)
EP (3) EP3452829B1 (enExample)
JP (3) JP7240712B2 (enExample)
AU (3) AU2017260806B9 (enExample)
BR (1) BR112018072498A2 (enExample)
CA (2) CA3286798A1 (enExample)
DK (1) DK3452829T3 (enExample)
ES (1) ES2974307T3 (enExample)
FI (1) FI3452829T3 (enExample)
PL (1) PL3452829T3 (enExample)
PT (1) PT3452829T (enExample)
WO (1) WO2017190896A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3655778T (pt) * 2017-07-21 2023-08-18 Fundacio Hospital Univ Vall Dhebron Institut De Recerca Agrin como marcador de cancro do endométrio
EP4373973A1 (en) 2021-07-23 2024-05-29 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Biomarkers for endometrial cancer
CN113493838B (zh) * 2021-09-06 2021-11-23 北京泱深生物信息技术有限公司 子宫内膜癌相关的标志分子及其在诊断子宫内膜癌中的应用
KR102640230B1 (ko) * 2021-09-24 2024-02-22 가천대학교 산학협력단 C-peptide를 처리한 자궁내막 기질세포의 이동성 변화 기작을 이용한 자궁내막 관련질환의 진단 방법 및 자궁내막 관련질환 치료제의 스크리닝 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
AUPO573697A0 (en) * 1997-03-20 1997-04-10 Prince Henry's Institute Of Medical Research Diagnosis of endometrial cancer
WO2005061725A1 (en) * 2003-12-23 2005-07-07 Mount Sinai Hospital Methods for detecting markers associated with endometrial disease or phase
US20080090258A1 (en) 2006-06-28 2008-04-17 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Method and composition for diagnosing endometrial cancer
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
IN2012DN00707A (enExample) 2009-07-24 2015-06-19 Geadic Biotec Aie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YURKOVETSKY Z, ET AL., 2007, Gynecologic Oncology, 107(1):58–65 *

Also Published As

Publication number Publication date
US20230221323A1 (en) 2023-07-13
JP7492287B2 (ja) 2024-05-29
EP4610655A3 (en) 2025-12-10
JP7240712B2 (ja) 2023-03-16
CA3286798A1 (en) 2025-10-30
AU2017260806B2 (en) 2023-06-15
AU2023210591B2 (en) 2025-06-26
AU2023210591B9 (en) 2025-07-10
CA3022586A1 (en) 2017-11-09
JP2019516104A (ja) 2019-06-13
PT3452829T (pt) 2024-03-22
ES2974307T3 (es) 2024-06-26
EP3452829A1 (en) 2019-03-13
PL3452829T3 (pl) 2024-05-20
EP4610655A2 (en) 2025-09-03
EP4180814A3 (en) 2023-07-12
EP3452829B1 (en) 2024-01-24
JP2024116127A (ja) 2024-08-27
US20190137499A1 (en) 2019-05-09
BR112018072498A2 (pt) 2019-03-12
AU2023210591A1 (en) 2023-08-24
JP2023040246A (ja) 2023-03-22
FI3452829T3 (fi) 2024-03-20
AU2025223935A1 (en) 2025-09-18
WO2017190896A1 (en) 2017-11-09
DK3452829T3 (da) 2024-03-25
AU2017260806A1 (en) 2018-12-13
EP4180814A2 (en) 2023-05-17

Similar Documents

Publication Publication Date Title
AU2023210591B2 (en) Markers of endometrial cancer
Chen et al. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia
US20240011994A1 (en) Ctnb1 as a marker for endometrial cancer
WO2012039161A1 (ja) 新規血管炎の検査方法および検査用試薬
TWI842716B (zh) 泌尿道上皮細胞癌生物標記及其應用
KR102131860B1 (ko) 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
KR102128251B1 (ko) 아르기닌이 메틸화된 drd2에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
BR122025014970A2 (pt) Método e uso que compreendem kpym para o diagnóstico ou prognóstico de carcinoma endometrial, bem como kit para detectar o nível de expressão de kpym e outros marcadores
BR122023026792A2 (pt) Método e uso da combinação dos marcadores perm e clic1 como marcadores in vitro para diagnosticar ou prognosticar carcinoma endometrial, bem como kit para detectar nível de expressão proteica
BR122024027006A2 (pt) Método para o diagnóstico de câncer endometrial em uma amostra de fluido uterino, kit e método implementado por computador para realizar o dito método diagnóstico e método para decidir ou recomendar um regime médico

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ MARKERS OF ENDOMETRIAL CANCER

PC1 Assignment before grant (sect. 113)

Owner name: FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA

Free format text: FORMER APPLICANT(S): LUXEMBOURG INSTITUTE OF HEALTH (LIH); FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA; INSTITUT DE RECERCA BIOMEDICA DE LLEIDA FUNDACIO DR. PIFARRE

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)